To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

324

Participants

Timeline

Start Date

June 27, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

June 30, 2025

Conditions
Type 2 Diabetes
Interventions
DRUG

HDM1002 50 mg

HDM1002 tablets, 50 mg once daily, 12 weeks

DRUG

HDM1002 100 mg

HDM1002 tablets, 100 mg once daily, 12 weeks

DRUG

HDM1002 200 mg

HDM1002 tablets, 200 mg once daily, 12 weeks

DRUG

HDM1002 400 mg

HDM1002 tablets, 400 mg once daily, 12 weeks

DRUG

HDM1002 200 mg BID

HDM1002 tablets, 200 mg twice daily, 12 weeks

DRUG

Placebo

Matching placebo will be provided

Trial Locations (31)

100039

The Chinese People's Liberation Army General Hospital, Beijing

Unknown

Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing

Peking University Shougang Hospital, Beijing

Cangzhou Central Hospital, Cangzhou

The Second Hospital of Jilin University, Changchun

The Fourth Hospital of Changsha City, Changsha

The Third Hospital of Changsha City, Changsha

Chengdu Second People's Hospital, Chengdu

The Affiliated Hospital of Chengdu University, Chengdu

Three Gorges Hospital Affiliated to Chongqing University, Chongqing

The First Hospital of Handan City, Handan

Zhejiang Provincial People's Hospital, Hangzhou

The Fourth Affiliated Hospital of Harbin Medical University, Harbin

The Second Affiliated Hospital of Anhui Medical University, Hefei

Huizhou Central People's Hospital, Huizhou

Huzhou Central Hospital, Huzhou

Jinan Central Hospital, Jinan

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

The Third People's Hospital of Luoyang City, Luoyang

The Second Affiliated Hospital of Nanjing Medical University, Nanjing

The First Affiliated Hospital of Nanyang Medical College, Nanyang

The First People's Hospital of Nanyang City, Nanyang

Panjin Liaohe Oilfield General Hospital, Panjin

The First Hospital of Qinhuangdao City, Qinhuangdao

Suzhou Municipal Hospital, Suzhou

The First Hospital of Shanxi Medical University, Taiyuan

Tonghua Central Hospital, Tonghua

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

Xuzhou Cancer Hospital, Xuzhou

Yueyang People's Hospital, Yueyang

The Second Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY

NCT06481085 - To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter